Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Resolution of chronic synovitis with Emicizumab?
Emicizumab continues to reshape our understanding of joint outcomes in severe Hemophilia A — transforming not only bleeding prevention, but also long‑term joint health.
At EAHAD2026, this poster by Matteo Di Minno, using HEAD‑US and HJHS in 52 adults on long‑term Emicizumab prophylaxis showed:
- Significant improvement in hypertrophic synovium scores over ≥2 years
- >50% of joints with hypertrophic synovium at baseline showed reduction or resolution
- Very few de‑novo HS findings in previously unaffected joints, suggesting structural joint protection in routine practice
Interestingly, joints with pre‑existing degenerative changes improved the least – a strong reminder that timing of effective prophylaxis still matters.
It will be particularly interesting to see how these real‑world imaging data will align with the ongoing Phase IV Beyond ABR study (NCT05181618), which is exploring broader health and joint outcomes under Emicizumab.”
Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation